Download Unicorn Signals App

Powered By EquityPandit
 Signals, Powered By  EquityPandit
STOCK MARKET

Gland Pharma Ltd Slips For Fifth Straight Session

Gland Pharma received tentative approval from the USFDA for its Angiotensin II Injection.

On National Stock Exchange (NSE), Gland Pharma Ltd stock is quoting at Rs 2230, down 0.75 per cent. In the year 202, the stock was compared to a 2 per cent in NIFTY and an 11.35 per cent spurt in the Nifty Metal index. Gland Pharma Ltd fell for a fifth straight session on Tuesday. The company’s stock is quoting at Rs 2230, down 0.75 per cent in morning trade. The benchmark NIFTY is up around 1.65 per cent today, quoting 17913.15. The Sensex is at 60059.48, up 1.55 per cent. Gland Pharma Ltd lost around 5.9 per cent in August month.

Meanwhile, the Nifty Metal index, of which Gland Pharma Ltd is a constituent, increased by around 0.55 per cent in August. Currently, the stock is quoting at 12369.6, up 2.33 per cent on the day. The volume in the stock stood at 1.11 lakh shares on Tuesday, compared to the daily average of 2.54 lakh shares in August. As of June end, the private equity of the company’s stock is 33.89 based on TTM earnings. 

Earlier a few months ago, the company’s stock was quoting at Rs 2870, down 0.16 per cent on the NSE. The benchmark NIFTY is down around 0.43 per cent daily, at 16056.3. The Sensex is at 53878.74, down 0.32 per cent. Gland Pharma Ltd lost around 8.68 per cent in April month. Around 6.19 per cent in April is recently quoted at 12691.6, down 0.63 per cent on the day. The volume in the stock stood at 2.32 lakh shares on May 25 2022, compared to the daily average of 1.95 lakh shares in April. The PE of the stock is 38.99 based on TTM earnings ending March 22.

Get Daily Prediction & Stocks Tips On Your Mobile